Law stated as at 16 Dec 2008 • USA (National/Federal)
On 16 December 2008, the US Federal Trade Commission (FTC) filed a complaint in the US District Court for the District of Minnesota alleging that Ovation Pharmaceuticals, Inc.'s 2006 acquisition of the drug NeoProfen violated the US antitrust laws. The FTC seeks equitable relief to resolve its allegations, including divestiture and disgorgement of the profits resulting from the acquisition.